Vimarsana
Biggest News Aggregation in the World

Page 2 - Call Link News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Call Link. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Call Link Today - Breaking & Trending Today

KalVista Pharmaceuticals Reports Phase 3 KONFIDENT Trial Meets All Endpoints for Sebetralstat as First Oral On-demand Therapy for Hereditary Angioedema - Vimarsana News

KalVista Pharmaceuticals Reports Phase 3 KONFIDENT Trial Meets All Endpoints for Sebetralstat as First Oral On-demand Therapy for Hereditary Angioedema

– Sebetralstat 300 mg achieved beginning of symptom relief in 1.6 hours – – Safety profile comparable to placebo – – On track for submission of new drug application to U.S. FDA in the...

Investegate | Company Announcement - Vimarsana News

Investegate | Company Announcement

Investegate announcements from 4Q 2023 Results Announcement

Investegate | Company Announcement - Vimarsana News

Investegate | Company Announcement

Investegate announcements from 4Q 2023 Results Announcement

Longboard Pharmaceuticals Announces Positive Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs) - Vimarsana News

Longboard Pharmaceuticals Announces Positive Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)

Bexicaserin achieved a median seizure reduction of 53.3% in countable motor seizures compared to 20.8% in the placebo group across the DEE study population A median seizure reduction of 72.1% in...

Longboard Pharmaceuticals to Host Call to Discuss Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs) - Vimarsana News

Longboard Pharmaceuticals to Host Call to Discuss Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)

• Conference call and webcast to be held tomorrow, January 2, at 8:30am ET ...